Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• Allopurinol adherence and its predictors in gout: a national cohort study in US veterans.1 passage
• Anakinra for severe forms of COVID-19: a cohort study.1 passage
• Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.1 passage
• Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.1 passage
• Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study.1 passage
• Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study.1 passage
• COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses.1 passage
• COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study.1 passage
• COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study.1 passage
• COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.1 passage
• COVID-19 vasculitis and novel vasculitis mimics.1 passage
• COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study.1 passage
• Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout.1 passage
• Clinical and molecular associations with outcomes at 2 years after acute knee injury: a longitudinal study in the Knee Injury Cohort at the Kennedy (KICK).1 passage
• Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study.1 passage
• Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective.1 passage
• Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.1 passage
• Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach.1 passage
• Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis.1 passage
• Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.1 passage
• Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial.1 passage
• Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort.1 passage
• Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study.1 passage
• GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.1 passage
• Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.1 passage
• Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.1 passage
• Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases.1 passage
• Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.1 passage
• Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?1 passage
• Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study.1 passage
• Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.1 passage
• Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.1 passage
• Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study.1 passage
• Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study.1 passage
• Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative.1 passage
• Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.1 passage
• Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.1 passage
• Of mice and men: converging on a common molecular understanding of osteoarthritis.1 passage
• Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study.1 passage
• Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study.1 passage
• Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study.1 passage
• SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study.1 passage
• Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial.1 passage
• Serious postoperative complications and reoperation after carpal tunnel decompression surgery in England: a nationwide cohort analysis.1 passage
• Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome.1 passage
• Stratified care versus usual care for management of patients presenting with sciatica in primary care (SCOPiC): a randomised controlled trial.1 passage
• Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controlled trial and economic evaluation.1 passage
• Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial.1 passage
• Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study.1 passage
• The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.1 passage
• The immunology of COVID-19: is immune modulation an option for treatment?1 passage
• The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study.1 passage
• The role of antirheumatics in patients with COVID-19.1 passage
• Therapeutic implications of ongoing alveolar viral replication in COVID-19.1 passage
• Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.1 passage
• Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial.1 passage
• Tocilizumab in patients with severe COVID-19: a retrospective cohort study.1 passage